![]() ![]() ![]() ![]() ![]() |
![]() ![]() ![]() ![]() ![]() |
The most commonly reported adverse events were application site reactions, dry mouth, constipation, diarrhea, dysuria, and abnormal vision. OXYTROL is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma and in patients who are at risk for these conditions. OXYTROL is also contraindicated in patients who have demonstrated hypersensitivity to oxybutynin or other components of the product. OXYTROL should be administered with caution in the following patients: those with hepatic or renal impairment; clinically significant bladder outflow obstruction; gastrointestinal obstructive disorders because of the risk of gastric retention; patients with gastroesophageal reflux.
Please see Prescribing Information.
Site Map Site Last Updated: 2006-07-11
Copyright © 2003 - 2008 Watson Pharma, Inc. All rights reserved.
Legal/Copyright Disclaimer Privacy Policy Important Safety Information









